2028 Safety Sales 
Pharmaceutical Technology
OCTOBER 5, 2022
According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year.
PM360
JANUARY 24, 2025
The use of medicines worldwide grew by 14% over the past five years, and is expected to grow an additional 12% by 2028. Some countries require local studies due to different safety and efficacy results. Healthcare expenses in emerging markets are expected to grow and reach parity with developed nations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 16, 2022
Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.
PM360
SEPTEMBER 21, 2023
Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re
Pharmaceutical Technology
DECEMBER 16, 2022
GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales.
Pharmaceutical Technology
DECEMBER 11, 2022
In the pirtobrutinib safety cohort, only 2.6% GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8 The mOS was 13.1 months, which in a historical context, is an improvement in the natural disease course of these patients. billion for Calquence.
Pharmaceutical Technology
OCTOBER 28, 2022
The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 billion and $812 million in 2028.
Expert insights. Personalized for you.
111 
Let's personalize your content